1. Fludarabine Metabolite Level on Day Zero Does Not Affect Outcomes of Hematopoietic Cell Transplantation in Patients with Normal Renal Function 
Cameron D. Griffiths, MD, Ella S.M. Ng, MSc, Bill Kangarloo, MSc., Tyler S. Williamson, PhD, Reanne Booker, Ping Yue, MD, Peter Raymond Duggan, MD, Mary Lynn Savoie, MD, FRCPC, Chris Brown, MD, Andrew Daly, James A. Russell, MA, MB, Jan Storek, MD, PhD 
Biology of Blood and Marrow Transplantation 
Volume 20, Issue 2, Pages S224-S225 (February 2014)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1
No significant difference in day 0 F-ara-A levels between patients with vs without GVHD, CMV reactivation above our threshold for preemptive antiviral therapy (25,000 IU/mL plasma), post-transplant lymphoproliferative disorder (PTLD), relapse, non-relapse death or death due to any cause. For each clinical outcome, p was >0.05 (range, ). Mann-Whitney-Wilcoxon test was used. “cGVHD NST” means chronic GVHD needing systemic therapy.
Biology of Blood and Marrow Transplantation  , S224-S225DOI: ( /j.bbmt )
Copyright © Terms and Conditions